Implications of stroke prevention trials: Treatment of global risk

Neurology

Volumn 65, Issue 1, 2005, Pages 17-21

  Elkind, Mitchell S V ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL; PLACEBO; RAMIPRIL; SIMVASTATIN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DRUG CHOICE; DRUG INDICATION; DYSLIPIDEMIA; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; COMORBIDITY; GUIDELINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 22044450091     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000171745.13592.cb     Document Type: Review

References (36)

1. Nilasena DS, Kresowik TF, Wiblin RT, et al. Assessing patterns of tPA use in acute stroke. Stroke 2002;33:354. Abstract.
2. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001;358:1033-1041.
3. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
4. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-2225.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-322.
6. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
8. The Stroke Council. Statins after ischemic stroke and transient ischemic attack: an advisory statement from the Stroke Council, American Heart Association and American Stroke Association. Stroke 2004;35: 1023.
9. Available at www.fda.gov/bbs/topics/ANSWERS/2003/ANS01213.html. Posted April 16, 2003. Accessed January 22, 2005.
10. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2004;126:483S-512S.
11. Wolf PA, Clagett GP, Easton JD, et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 1999;30:1991-1994.
12. Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004;109(suppl 1):II42-II48.
13. Ridker PM, Cannon CP, Morrow D, et al. C-Reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28.
14. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
15. Amarenco P, Bogousslavsky J, Callahan AS, et al. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Cerebrovasc Dis 2003;16:389-395.
16. Sacco RL. Risk factors, outcomes, and stroke subtypes for ischemic stroke. Neurology 1997; 49(suppl 4):S39-S44.
17. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-767.
18. Adams RJ, Chimowitz MI, Alpert JS, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke. A scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/ American Stroke Association. Circulation 2003;108:1278-1290.
19. Albers GW. Choice of endpoints in antiplatelet trials. Which outcomes are most relevant to stroke patients? Neurology 2000;54:1022-1028.
20. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. Br Med J 2002;324:1570-1576.
21. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001;103:163-182.
22. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774.
23. Iadecola C, Gorelick PB. Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke 2004;35:348-350.
24. Pedelty L, Gorelick PB. Chronic management of blood pressure after stroke. Hypertension 2004;44:1-5.
25. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289: 2560-2572.
26. Rose G. The strategy of preventive medicine. Oxford, UK: Oxford University Press, 1992.
27. Kernan WN, Viscoli CM, Brass LM, et al. The Stroke Prognosis Instrument II (SPI II). A clinical prediction instrument for patients with transient ischemia and non-disabling ischemic stroke. Stroke 2000;31: 456-462.
28. Meissner I, Whisnant JP, Garraway WM. Hypertension management and stroke recurrence in a community (Rochester, Minnesota, 1950-79). Stroke 1988;19:459-463.
29. Hankey GJ, Slattery JM, Warlow CP. Transient ischaemic attacks: which patients are at high (and low) risk of serious vascular events? J Neurol Neurosurg Psychiatry 1992;55:640-652.
30. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
31. Grundy S, Cleeman J, Merz C, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-239.
32. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83: 356-362.
33. D'Agostino, RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication: the Framingham Study. Stroke 1994;25:40-43.
34. Lumley T, Kronmal RA, Cushman M, Manolio TA, Goldstein S. A stroke prediction score in the elderly: validation and Web-based application. J Clin Epidemiol 2002;55:129-136.
35. Dhamoon MS, Sciacca RR, Sacco RL, Elkind MSV. Risk of myocardial infarction and vascular death after first ischemic stroke: the Northern Manhattan Stroke Study. Ann Neurol 2004;56 (suppl 8):S1. Abstract.
36. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI. Insulin resistance and risk for stroke. Neurology 2002;59:809-815.